Navigation Links
ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing
Date:4/8/2009

NORTH BRUNSWICK¿ N.J.¿ April 8 /PRNewswire/ -- ORTHOCON¿ Inc. today announced that Paul R. Sohmer, M.D. has joined the company as President and Chief Executive Officer. The company also announced the closing of a $25 million round of financing led by top-tier healthcare investors.

ORTHOCON is developing innovative implantable devices that deliver therapeutics to bone. The Company's versatile technology platform may be leveraged to deliver a variety of therapeutic agents. ORTHOCON's lead product is a novel extended release local anesthetic bone hemostat designed to stop bleeding and to provide local pain relief. The Company expects to initiate a pivotal clinical trial with this product in the second half of 2009.

"I am thrilled to join the ORTHOCON team," said Dr. Sohmer. "I look forward to working with our management team and our investors to build our Company and to bring an array of novel products to market based on ORTHOCON's innovative platform technology."

ORTHOCON's $25 million financing was co-led by ProQuest Investments and Canaan Partners. The round also included significant participation from ORTHOCON's existing stockholder BB BIOTECH Ventures. Joyce Tsang, Ph.D., General Partner of ProQuest Investments and Dr. Sohmer both joined ORTHOCON's board of directors.

"ORTHOCON is a great late-stage company with the ideal combination of a promising technology platform, a leadership team with a proven track record and great syndicate partners," commented Joyce Tsang, Ph.D. "We believe now is the perfect time to back ORTHOCON and we are delighted to be part of the Company."

"The addition of Paul Sohmer to the team and the strengthening of the finances of the Company through ProQuest joining in this round mark a great milestone for the Company," said ORTHOCON's Chairman and Canaan Partners' board representative, Seth Rudnick, M.D. "With approved products and an advanced
'/>"/>

SOURCE ORTHOCON, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Announces Clarinex(R) Settlement Agreement
2. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
3. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
4. Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies
5. Shamir Optical Industry Ltd. Announces Receipt of Notice from Nasdaq of Noncompliance with Nasdaq Audit Committee Composition Requirements
6. UnitedLex Announces Strategic Alliance with Oval Ideas to Enable Superior Patent Analytics
7. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
8. Health Career Agents Announces SBA Pre-Approval Program to Launch a Healthcare Recruiting Business
9. M2S Announces Agreement with AG Mednet to Provide Clinical Trial Sponsors with More Options for Efficient Image Transfer and Collection
10. Immucor Announces Fiscal Third Quarter Results
11. IGI Announces Portal Designed to Maximize Data Sharing Between Hospitals and Their Affiliated Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Inc. Magazine recently ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ... such as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, ... early exposure as members of the Inc. 500|5000. ...
(Date:8/20/2014)... 2014 Building on growing success ... predicted stage iii and iv pressure ulcers with ... approached 90%. A company spokesperson commented that these ... or academic settings. The resulting capabilities can be ... hospital-acquired conditions to help providers avoid financial losses ...
(Date:8/20/2014)... 2014 Ticketability.com has Theresa ... fair prices. The well-known medium has been thrilling many ... touring in 19 cities, with tickets becoming available August ... will visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, ... Hills and San Diego. The medium’s fans can obtain ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... The “Human Insulin Market by Product Type ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2019” provides a detailed overview ... trends,and strategies impacting the global human insulin market ... revenue and share analysis. , Browse 110 market ...
Breaking Medicine News(10 mins):Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4
... Georgia Center for Biotechnology and Genomic Medicine has been selected ... of children involved in a worldwide study of the causes ... in the mammoth study that will eventually follow 8,000 at-risk ... collecting blood every three months as they go. , ...
... Bulletin,Board: DSCI), a provider of advanced wound care products, ... its agency for investor relations and,corporate communications., "Derma ... in part to our,recent acquisition of the first aid ... our MEDIHONEY(TM) products, and the licensing of DSC127, a,novel ...
... is the,most significant advancement in surgical medicine in ... variety of academic and private hospitals around,the world, ... globally. Despite the fact that both StomaphyX(TM) and,EsophyX(TM) ... U.S. centers,have already been trained to perform these ...
... ATLANTA, December 17, 2007A new American Cancer Society report ... cancer cases and 7.6 million cancer deaths (about 20,000 ... comes from the first-ever Global Cancer Facts & Figures, ... of Facts & Figures publications. The report estimates that ...
... with a team at the University of California, San ... affects a childs risk of getting Kawasaki disease (KD), ... throughout the body. The genetic variation influences immune ... as the risk of developing coronary artery aneurysms ...
... activities that stretch youngsters, creativity and forge bonds with ... -- When you,re Christmas shopping for toys, ignore the ... healthy childhood development and reinforce personal relationships. , "It,s ... imagination, manipulation, and change. If a toy is static ...
Cached Medicine News:Health News:MCG selected as RNA laboratory for worldwide diabetes study 2Health News:Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications 2Health News:Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications 3Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 2Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 3Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 4Health News:New report estimates 12 million cancer deaths worldwide 2Health News:International research collaboration narrows focus on genetic cause of Kawasaki disease 2Health News:International research collaboration narrows focus on genetic cause of Kawasaki disease 3Health News:Picking the Right Toys Isn't Child's Play 2
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/19/2014)... BIRMINGHAM, Ala. , Aug. 19, 2014  The Alabama ... re-affirmed that patients can sue drug makers who mislead doctors ... cause harmful side‑effects.  The case is Weeks v. Wyeth, and ... drug makers in that same case last year. Heninger Garrison ... represent the patient in the case, Danny Weeks ...
(Date:8/19/2014)... -- Minimally Invasive Devices Inc. (MID), a ... that Mitsubishi Corporation has formally agreed to exclusively distribute ... Japan . MID anticipates that FloShield will ... in the second half of 2015. ... Storz GMBH & Co. (endoscopic instruments and devices) in ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation....
... is the result of years of research ... innovation and value, continues to bring you ... CT 200 is faster and easier to ... The CT 200 is the latest innovation ...
The Excel Series from DGH-KOI is an excellent choice for the ophthalmic surgeon performing cataract and other general ophthalmic procedures. With a broad range of blade options and our special Excel ...
New! Visually superior, micrometer handle, single foot plate, blade extends to 3.0 mm....
Medicine Products: